List of Actoplus Met drug patents

Actoplus Met is owned by Takeda Pharms Usa.

Actoplus Met contains Metformin Hydrochloride; Pioglitazone Hydrochloride.

Actoplus Met has a total of 2 drug patents out of which 0 drug patents have expired.

Actoplus Met was authorised for market use on 29 August, 2005.

Actoplus Met is available in tablet;oral dosage forms.

The generics of Actoplus Met are possible to be released after 03 February, 2029.

ACTOPLUS MET's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101660 TAKEDA PHARMS USA Solid preparation
Jan, 2027

(3 years from now)

US9320714 TAKEDA PHARMS USA Tablet
Feb, 2029

(5 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2005

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ACTOPLUS MET family patents

7

Japan

4

United States

2

Portugal

2

Spain

2

Korea, Republic of

2

Canada

2

New Zealand

2

European Union

1

Israel

1

South Africa

1

Denmark

1

Mexico

1

Australia

1

Hong Kong

1

Russia

1

Slovenia

1

Morocco

1

Norway

1

Costa Rica

1

Colombia

1

Brazil

1

Cyprus

1

Poland

1

China

1

Ukraine

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in